The massive revenue inflection from RYONCIL commercialization and the completion of the Phase 3 CLBP trial enrollment are significant catalysts. Traders should watch for the mid-CY2027 rexlemestrocel-L readout and any updates on the adult SR-aGvHD label expansion trial. The stock has historically shown high volatility around catalysts, so position sizing should account for binary risk.
Price Chart
Executive Summary
Mesoblast reported FY2026 total revenue of $120.3M, up 7x from $17.2M in FY2025, driven by the first full year of RYONCIL commercial launch. Net loss narrowed 44% to $57.5M, and the company completed enrollment in a pivotal Phase 3 trial for rexlemestrocel-L in chronic low back pain. The massive revenue growth and pipeline progress are bullish, but the company remains unprofitable and the stock has a history of volatile post-earnings moves.
Key Financial Metrics
Key Facts
- FY2026 total revenue of $120.3M vs $17.2M in FY2025, a 599% increase.
- RYONCIL net revenue of $115.2M in its first full commercial year.
- Gross profit of $103.6M vs $5.1M in FY2025.
- Net loss reduced 44% to $57.5M from $102.1M.
- Phase 3 trial of rexlemestrocel-L for chronic low back pain completed enrollment with 350 patients; top-line results expected mid-CY2027.
- Cash balance of $103M at period end; entered a $125M non-dilutive credit facility.
- EPS of -$0.0444 per share (basic and diluted) vs -$0.0846 in FY2025.
Financial Impact
Revenue increased by $103.1M YoY; net loss improved by $44.6M YoY.
Risk Factors
- RYONCIL revenue growth may decelerate as initial launch pent-up demand normalizes.
- Phase 3 CLBP trial results are binary and not expected until mid-CY2027.
- Company remains unprofitable with accumulated losses of $1.07B.
- Dependence on successful label expansion into adult SR-aGvHD for sustained growth.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3351749 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | 20-F | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 27, 2026 5w ago | Press Release | $18.18 $15.48 | ▼ −14.85% | ▼ −14.34% | $14.07 (−22.58%) |
Aug 24, 2026 5w ago | 6-K | $16.64 $15.92 | ▼ −4.33% | ▼ −5.64% | $14.07 (−15.41%) |
Aug 17, 2026 6w ago | Press Release | $17.02 $14.74 | ▼ −13.40% | ▼ −11.42% | $14.07 (−17.30%) |
Jul 30, 2026 9w ago | 6-K | $14.55 $18.18 | ▲ +24.95% | ▲ +20.98% | $14.07 (−3.26%) |
Jul 14, 2026 11w ago | 6-K | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 14, 2026 11w ago | Press Release | $16.74 $16.92 | ▲ +1.08% | ▼ −1.42% | $14.07 (−15.92%) |
Jul 10, 2026 12w ago | 6-K | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 10, 2026 12w ago | Press Release | $15.44 $15.94 | ▲ +3.24% | ▲ +0.81% | $14.07 (−8.84%) |
Jul 1, 2026 13w ago | 6-K | $14.09 $14.13 | ▲ +0.28% | ▲ +2.47% | $14.07 (−0.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access